How formulation affects CoQ10 blood exposure

Editorial study summary

Study type

Double-blind human crossover pharmacokinetic comparison.

Product relevance

Comparative context. The study included both reduced ubiquinol and oxidized ubiquinone preparations and did not test the DR.MORGAN cocrystal.

Sample or population

14 healthy young adults.

Studied dose

A single 100 mg dose for each of seven formulations.

Duration

Blood measurements over 48 hours. At least four weeks separated doses.

Finding

Blood exposure varied substantially. One ubiquinol and one ubiquinone softgel were among the best-absorbed preparations, and the formulation matrix affected exposure.

Limitations

Form and formulation were both relevant. A single-dose blood measurement does not establish clinical benefit or general superiority of one form.

Study quality

Within-participant comparison using serial plasma measurements. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.

Funding and disclosures

Funding and conflicts were not verified from the abstract.

The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.

Reference

1. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019. DOI 10.1016/j.nut.2018.05.020. PMID 30153575